<DOC>
	<DOC>NCT00144586</DOC>
	<brief_summary>This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA220JP or MRA221JP.</brief_summary>
	<brief_title>Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Inclusion criteria RA patients who participated in the previous studies Patients who completed the last observation in the previous studies Patients who were confirmed to have no problems with safety in the previous studies. Exclusion criteria Patients with Class IV Steinbrocker functional disorder at evaluation within 4 weeks before treatment with the investigational product Patients who were not enrolled by 3 months after the last observation day of the previous study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>